Opinion statement
The paraneoplastic syndrome caused by Ma2/Ta antibodies alone (not in conjunction with Ma1 or Ma3 antibodies) varies in presentation from classic limbic encephalitis. The Ma2 syndrome may present with symptoms referable to the brainstem, diencephalon, and limbic system. These clinical symptoms are accompanied by MRI changes and abnormal electroencephalographic findings. It is important to recognize when the encephalitic syndrome is secondary to Ma2 paraneoplastic antibodies, as the patients improve or stabilize most often when the underlying carcinoma is treated. Treatment of the paraneoplastic syndrome begins with recognition of the symptoms, such as memory impairment, seizures, sleep disturbances, bradykinesia or hypokinesia, and eye movement abnormalities. If a primary tumor is discovered during the workup, it should be removed and treated with the most up-to-date oncologic treatment available. In addition to oncologic treatment, the syndrome may be treated with an immunosuppressant regimen to optimize the neurologic outcome. Leaving the patient untreated will result in decline and eventual death from the cancer itself or from complications of the paraneoplastic syndrome.
Similar content being viewed by others
References and Recommended Reading
Dalmau J, Graus F, Villarejo A, et al.: Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004, 127:1831–1844.
Tuzun E, Dalmau J: Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007, 13:261–271.
Gultekin S, Rosenfeld MR, Voltz R, et al.: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain 2000, 123:1481–1494.
Graus F, Delattre JY, Antoine JC, et al.: Recommended diagnostic criteria for paraneoplastic neurological syndrome. J Neurol Neurosurg Psychiatry 2004, 75:1135–1140.
Brierly JB, Corsellis JAN, Hierons R, Nevin S: Sub acute encephalitis of later adult life, mainly affecting the limbic areas. Brain 1960, 83:357–368.
Corsellis JAN, Goldberg GJ, Norton AR: “Limbic Encephalitis” and its association with carcinoma. Brain 1968, 91:481–496.
Castle J, Sakonju A, Dalmau J, Newman-Toker DE: Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple’s disease. Nat Clin Pract Neurol 2006, 2:566–572.
Mathew RM, Vandenberghe R, Garcia-Merino A, et al.: Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 2007, 68:900–905.
Bennett JL, Galetta SL, Frohman LP, et al.: Neuro-ophthalmologic manifestations of a paraneoplastic syndrome and testicular carcinoma. Neurology 1999, 52:864–867.
Bataller L, Dalmau J: Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol 2004, 17:3–8.
Peterson K, Rosenblum MK, Kotanides H, Posner JB: Paraneoplastic cerebellar degeneration I. A clinical analysis of 55 anti-Yo antibody positive patients. Neurology 1992, 42:1931–1937.
Schott JM: Limbic encephalitis: a clinician’s guide. Pract Neurol 2006, 6:143–153.
Giannopoulou C: Navigating the paraneoplastic neurological syndromes. Eur J Nucl Med 2002, 30:333–338.
de Beukelaar JW, Sillevis Smitt PA: Managing paraneoplastic neurological disorders. Oncologist 2006, 11:292–305.
Travis LB, Fosså SD, Schonfeld SJ, et al.: Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97:1354–1365.
van den Belt-Dusebout AW, de Wit R, Gietema JA, et al.: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007, 25:4370–4378.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kraker, J. Treatment of anti-Ma2/Ta paraneoplastic syndrome. Curr Treat Options Neurol 11, 46–51 (2009). https://doi.org/10.1007/s11940-009-0007-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-009-0007-7